Sleep Disorders Group, Department of EEE, Melbourne School of Engineering, The University of Melbourne, 3rd Floor, Room no. 344, Parkville, Melbourne, VIC, 3010, Australia.
Neurotox Res. 2013 Oct;24(3):407-59. doi: 10.1007/s12640-013-9407-2. Epub 2013 Jul 3.
Late onset Alzheimer's disease (AD) is the most common cause of progressive cognitive dysfunction and dementia. Despite considerable progress in elucidating the molecular pathology of this disease, we are not yet close to unraveling its etiopathogenesis. The hippocampus is at the epicenter of cognition being associated with learning and memory. A battery of neurotoxic modifiers has been delineated that may unleash deleterious heterogeneous pathologic impacts. Synergistically they target hippocampus causing its neuronal degeneration, gray matter volume atrophy, and progressive cognitive decline. The neurotoxic factors include aging, stress, depression, hypoxia/hypoxemia, hypertension, diabetes, obesity, alcohol abuse, smoking, malnutrition, and polypharmacy-to name a few. Addressing "upstream pathologies" due to these multiple and heterogeneous neurotoxic modifiers vis-a-vis hippocampal dysfunction is of paramount importance. The downstream-generated inflammatory cytokines, mitochondrial dysfunction, oxidative stress, hypoperfusion, excitotoxicity, amyloid beta, and neurofibrillary tangles may then trigger and sustain neurocognitive pathology. The failure of clinical trials in AD is due in part to this complex multifactorial neurotoxic-pathophysiological labyrinth. The key is to employ appropriate preventive and treatment strategies prior to significant hippocampus damage and its dysfunction. Prevention/reversal of the diverse neurotoxic impacts, delineated here, should be an integral part of therapeutic armamentarium, in order to ameliorate hippocampus dysfunction and to enhance memory in aging, mild cognitive impairment, and AD. Throughout, the paper highlights both the challenges presented by the ever present neurotoxic onslaught, and the opportunities to overcome them. Hence, arresting AD pathogenesis is achievable through early intervention. A targeted approach may ameliorate neurocognitive pathology and attenuate memory deterioration.
迟发性阿尔茨海默病(AD)是进行性认知功能障碍和痴呆的最常见原因。尽管在阐明这种疾病的分子病理学方面取得了相当大的进展,但我们还远未揭示其病因发病机制。海马体位于认知的中心,与学习和记忆有关。已经确定了一系列神经毒性修饰剂,它们可能释放出有害的异质病理影响。它们协同作用于海马体,导致其神经元变性、灰质体积萎缩和进行性认知衰退。神经毒性因素包括衰老、应激、抑郁、缺氧/低氧血症、高血压、糖尿病、肥胖、酗酒、吸烟、营养不良和多种药物治疗等。解决这些多种异质神经毒性修饰剂引起的“上游病理学”以及海马功能障碍至关重要。随后产生的炎症细胞因子、线粒体功能障碍、氧化应激、灌注不足、兴奋毒性、β淀粉样蛋白和神经原纤维缠结可能引发并维持神经认知病理学。AD 临床试验的失败部分归因于这种复杂的多因素神经毒性-病理生理迷宫。关键是在海马体损伤及其功能障碍之前,采用适当的预防和治疗策略。预防/逆转这里描述的各种神经毒性影响,应该成为治疗手段的一个组成部分,以改善海马体功能障碍,并增强衰老、轻度认知障碍和 AD 中的记忆力。整篇文章都强调了不断存在的神经毒性攻击带来的挑战,以及克服这些挑战的机会。因此,通过早期干预可以阻止 AD 的发病机制。有针对性的方法可以改善神经认知病理学并减轻记忆恶化。